These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 12595861

  • 1. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2003 Feb; 145(2):e6. PubMed ID: 12595861
    [Abstract] [Full Text] [Related]

  • 2. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.
    Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, Michelson AD.
    Am Heart J; 2001 Nov; 142(5):790-8. PubMed ID: 11685164
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
    Abernethy DR, Pezzullo J, Mascelli MA, Frederick B, Kleiman NS, Freedman J.
    Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
    [Abstract] [Full Text] [Related]

  • 4. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
    Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G.
    J Invasive Cardiol; 2010 Jan; 22(1):2-6. PubMed ID: 20048389
    [Abstract] [Full Text] [Related]

  • 5. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
    Zahn R, Haubelt H, Bechtloff S, Schneider S, Frilling B, Rustige J, Marsalek P, Seidl K, Senges J, Hellstern P.
    Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
    [Abstract] [Full Text] [Related]

  • 6. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
    Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
    [Abstract] [Full Text] [Related]

  • 7. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR, Malik IS, Weerasinghe A, Poullis M, Nadra I, Haskard DO, Taylor KM, Landis RC.
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [Abstract] [Full Text] [Related]

  • 8. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 9. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG InvestigatorsDepartment of Cardiology, Cleveland Clinic Foundation, OH 44195, USA..
    N Engl J Med; 1997 Jun 12; 336(24):1689-96. PubMed ID: 9182212
    [Abstract] [Full Text] [Related]

  • 10. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.
    Am Heart J; 2006 Mar 12; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan 12; 63(1):8-15. PubMed ID: 10645045
    [Abstract] [Full Text] [Related]

  • 12. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 12; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 13. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 12; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 14. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK, Whitaker DA, Sobel BE, Schneider DJ.
    Thromb Res; 2004 Feb 12; 113(1):27-34. PubMed ID: 15081562
    [Abstract] [Full Text] [Related]

  • 15. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 12; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 16. Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.
    Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Esslinger HU, Breddin HK, Harder S.
    Br J Clin Pharmacol; 2001 Sep 12; 52(3):297-305. PubMed ID: 11560562
    [Abstract] [Full Text] [Related]

  • 17. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.
    Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE.
    Circulation; 1997 Dec 02; 96(11):3860-6. PubMed ID: 9403608
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C, Sesana M, Leonzi O, Cuccia C.
    J Cardiovasc Med (Hagerstown); 2006 Dec 02; 7(12):866-71. PubMed ID: 17122672
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of abciximab induced platelet blockade using a rapid point of care assay.
    Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Whang DD, Abbottsmith CW.
    J Thromb Thrombolysis; 1999 Jun 02; 7(3):265-76. PubMed ID: 10375388
    [Abstract] [Full Text] [Related]

  • 20. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy.
    Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, Michelson AD, Furman MI, Mueller MN, Moliterno DJ, Sane DC.
    Am Heart J; 2002 Apr 02; 143(4):602-11. PubMed ID: 11923796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.